Market Cap 6.73B
Revenue (ttm) 0.00
Net Income (ttm) -260.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 853,700
Avg Vol 435,614
Day's Range N/A - N/A
Shares Out 72.11M
Stochastic %K 57%
Beta 1.30
Analysts Strong Sell
Price Target $117.53

Company Profile

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) wh...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 357 7000
Address:
One Broadway, 14th Floor, Cambridge, United States
jb06000
jb06000 Oct. 21 at 3:56 PM
$NUVL take your profit jump to NUVB this will crash one approved.
0 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 18 at 2:29 PM
$NUVL 4 insiders just dumped another 11 million dollars worth of stock this week. Seems insiders have no confidence in the future of this company. Just look at that sea of red. https://www.secform4.com/insider-trading/1861560.htm
0 · Reply
vu_jade
vu_jade Oct. 17 at 2:55 AM
$NUVL ready to rock
0 · Reply
notreload_ai
notreload_ai Oct. 16 at 2:29 PM
$SNDX , $BDTX , $RVMD , $VSTM , $NUVL ... H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments. https://notreload.xyz/sndx-bdtx-rvmd-vstm-nuvl-buy-ratings/
0 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 16 at 1:56 PM
$NUVB This is completely f*****n nuts for this to be trading down right now as the XBI is trading up over 2.00 again and $NUVL is up another 2.70 on 90,000 volume, as the insiders there continue to dump their shares.
1 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 1:55 PM
Stifel has adjusted their stance on Nuvalent ( $NUVL ), setting the rating to Buy with a target price of 115.
0 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 16 at 2:46 AM
$NUVL Insiders dumped again two days ago.
0 · Reply
Doozio
Doozio Oct. 15 at 10:47 PM
$NUVL $NUVB scrabble bag some health happiness and 🐒🍌🧠⏰♾️
0 · Reply
jb06000
jb06000 Oct. 15 at 4:17 PM
$NUVL NUVB has realized revenue potential (now that its drug is approved), but NUVL is priced for a potentially greater, yet unproven, future. Investors are currently more excited about the potential superiority of NUVL's next-generation drugs than the current reality of NUVB's first commercial product.
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 2:09 PM
Cantor Fitzgerald updates rating for Nuvalent ( $NUVL ) to Overweight, target set at 135.
0 · Reply
Latest News on NUVL
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day

Sep 24, 2025, 6:30 AM EDT - 4 weeks ago

Nuvalent to Participate in the UBS 2025 Virtual Oncology Day


Nuvalent Appoints Christy Oliger to Board of Directors

Jun 18, 2025, 4:30 PM EDT - 4 months ago

Nuvalent Appoints Christy Oliger to Board of Directors


Nuvalent to Participate in Upcoming March Investor Conferences

Feb 28, 2025, 6:30 AM EST - 8 months ago

Nuvalent to Participate in Upcoming March Investor Conferences


Nuvalent: A Logical Acquisition Target

Jan 10, 2025, 1:22 PM EST - 10 months ago

Nuvalent: A Logical Acquisition Target


Nuvalent Appoints Grant Bogle to Board of Directors

Dec 9, 2024, 6:30 AM EST - 11 months ago

Nuvalent Appoints Grant Bogle to Board of Directors


Nuvalent: Promising Data Keeps Validating Pipeline And Platform

Sep 23, 2024, 12:34 PM EDT - 1 year ago

Nuvalent: Promising Data Keeps Validating Pipeline And Platform


Cancer Biotech Nuvalent's Stock Jumps on Positive Data

Sep 16, 2024, 11:18 AM EDT - 1 year ago

Cancer Biotech Nuvalent's Stock Jumps on Positive Data


Nuvalent Announces Public Offering of Common Stock

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Nuvalent Announces Public Offering of Common Stock


Nuvalent: Making Precise Progress In Its Oncology Pipeline

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Nuvalent: Making Precise Progress In Its Oncology Pipeline


Nuvalent (NUVL) CEO On The Future Of Cancer Treatments

Jun 17, 2024, 12:19 PM EDT - 1 year ago

Nuvalent (NUVL) CEO On The Future Of Cancer Treatments


Nuvalent: NVL-655 Could Bring Blockbuster Potential

Jun 14, 2024, 7:15 AM EDT - 1 year ago

Nuvalent: NVL-655 Could Bring Blockbuster Potential


jb06000
jb06000 Oct. 21 at 3:56 PM
$NUVL take your profit jump to NUVB this will crash one approved.
0 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 18 at 2:29 PM
$NUVL 4 insiders just dumped another 11 million dollars worth of stock this week. Seems insiders have no confidence in the future of this company. Just look at that sea of red. https://www.secform4.com/insider-trading/1861560.htm
0 · Reply
vu_jade
vu_jade Oct. 17 at 2:55 AM
$NUVL ready to rock
0 · Reply
notreload_ai
notreload_ai Oct. 16 at 2:29 PM
$SNDX , $BDTX , $RVMD , $VSTM , $NUVL ... H.C. Wainwright, Stifel, and Cantor Fitzgerald issue Buy ratings on five biotech stocks including Syndax, Black Diamond, Revolution Medicines, Verastem, and Nuvalent, citing breakthrough cancer treatments. https://notreload.xyz/sndx-bdtx-rvmd-vstm-nuvl-buy-ratings/
0 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 16 at 1:56 PM
$NUVB This is completely f*****n nuts for this to be trading down right now as the XBI is trading up over 2.00 again and $NUVL is up another 2.70 on 90,000 volume, as the insiders there continue to dump their shares.
1 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 1:55 PM
Stifel has adjusted their stance on Nuvalent ( $NUVL ), setting the rating to Buy with a target price of 115.
0 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 16 at 2:46 AM
$NUVL Insiders dumped again two days ago.
0 · Reply
Doozio
Doozio Oct. 15 at 10:47 PM
$NUVL $NUVB scrabble bag some health happiness and 🐒🍌🧠⏰♾️
0 · Reply
jb06000
jb06000 Oct. 15 at 4:17 PM
$NUVL NUVB has realized revenue potential (now that its drug is approved), but NUVL is priced for a potentially greater, yet unproven, future. Investors are currently more excited about the potential superiority of NUVL's next-generation drugs than the current reality of NUVB's first commercial product.
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 2:09 PM
Cantor Fitzgerald updates rating for Nuvalent ( $NUVL ) to Overweight, target set at 135.
0 · Reply
justiceforb_85
justiceforb_85 Oct. 14 at 7:48 PM
$NUVL adding.
0 · Reply
vu_jade
vu_jade Oct. 13 at 4:39 PM
$NUVL ready to rally
1 · Reply
vjtweet
vjtweet Oct. 8 at 6:19 PM
$NUVL opened a position again.
0 · Reply
MacroMage
MacroMage Oct. 5 at 2:49 PM
$NUVL Cloud technology growth. Testing resistance level. Volume confirmation needed. Sector momentum building.
0 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 4 at 5:53 PM
$NUVB Ask yourself why $NUVL's valuation is $7.5 billion, they don't even have a drug approved. Did you sell and now you are trying to get it cheaper?
1 · Reply
ISEEITALLTHETIME
ISEEITALLTHETIME Oct. 4 at 3:53 PM
$NUVB It has been non stop selling at $NUVL for the last two years. It brings in to question their confidence in their company's future. $NUVB on the other hand, has seen virtually no insider selling, but lots of insider buys.
0 · Reply
Quantumup
Quantumup Sep. 30 at 1:58 PM
Jefferies🏁 $NUVB Buy/$10 $NUVL $BMY Jefferies said: Lead asset Ibtrozi has full FDA approval for ROS1+ NSCLC w/ a broad line-agnostic label -- multi-year treatment duration could drive significant revenue stacking vs what Street forecasts. Pipeline provides upside optionality w/ safusidenib (IDH1m glioma) set to advance into phase 3 and '1511 novel oral drug conjugate approach w/ clinical update in 2H. Cash $608M runway into 1H28 (our est). Initiate at Buy w/ PT $10.
0 · Reply
outlawinvestor1
outlawinvestor1 Sep. 9 at 3:40 PM
2 · Reply
JarvisFlow
JarvisFlow Sep. 8 at 1:11 PM
Wedbush updates rating for Nuvalent ( $NUVL ) to Outperform, target set at 115.
0 · Reply
Doozio
Doozio Sep. 5 at 3:18 PM
$NUVL while da 🐑 in da HOOD get SKWD watching 🧠leader🐑 base.. out of the tightness the 🧠 spreads on the DLO 🐒🍌🧠⏰♾️
0 · Reply
IN0V8
IN0V8 Sep. 4 at 3:41 PM
$NUVL Opportunity Raymond James initiates coverage with outperform rating; PT $105
0 · Reply
Quantumup
Quantumup Aug. 20 at 3:56 PM
Piper Sandler (Aug. 18)🏁 $NUVL at an Overweight/$112. $RHHBY $PFE TAK NVS ABBV LLY JNJ $ZLAB $NUVB Piper Sandler said in its initiation report: Investors largely view $NUVL as a high quality precision oncology company but seem to be in a waiting pattern until we get closer to the 1L ALK data in a few years. We think the Street underestimates the near-term value creation over the next 18 months as we get (1) updated Ph II neladalkib data in 2L+ ALK NSCLC later this year which will confirm the degree of differentiation vs. lorlatinib, and by indirect comparison vs. alectinib, (2) initial commercial sales from zidesamtinib in 2026 in the ROS1 market which we think investors undervalue, and 3) potential initial data for NVL-330 in HER2+ NSCLC next year, in our view.
0 · Reply